A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to assess whether ladarixin treatment is effective in
preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in
adolescent and adult patients. The safety of ladarixin in the specific clinical setting will
be also evaluated.